International Department

On September 6, 2021,JW Therapeutics announced that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (relma-cel) ...Read more »

Equecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (R/RMM). On June 30,2023,China’s National Medical Products Admi...Read more »

On October 11, 2024,China’s National Medical Product Administration (NMPA) has approved  Investigational New Drug（IND）application for Inaticabtagene Autoleucel (CNCT19 Injection), a CD19-targeted autologous chimeric antigen receptor (CAR)-T cell therapy, to treat  Immune thrombocytopenia ...Read more »

On March 1st, 2024, China National Medical Products Administration (NMPA) approved the launch of CAR-T cell product Zevorcabtagene AutoLeucel (Zevor-cel, CT053) for the treatment of adult patients with relapsed or refractory multiple myeloma who had progressed after at least 3 lines of treatment(...Read more »